German OTC Marketing Round-Up: Allergy Launches From Novartis, Hevert, Dermapharm And Bencard
Executive Summary
OTC marketing news from Germany: A hard-won desloratadine launch from Novartis, two new products from Dermapharm, as well as homeopathic and probiotic alternatives from Hevert and Bencard.
You may also be interested in...
Are Rx-To-OTC Switches Worth The Trouble? Yes They Are, IQVIA Data Shows
The holy grail of consumer health innovation, Rx-to-OTC switches, are costly and hard to pull off. So, are they worth the effort? An analysis by IQVIA of desloratadine, which was switched in Germany 2020 by Novartis subsidiary, Hexal, shows that they are, with sales of OTC desloratadine products growing 112% between 2019 and 2020.
Novartis Wins Landmark Case Against German Government Over Desloratadine Switch
Generics giant Novartis through its Hexal subsidiary has won an important case against the German Ministry of Health over a delayed prescription-to-OTC switch of desloratadine, which shows European Union Member States have got the authority to switch at a national level centrally authorized drugs.
Life’s An Itch And Then You Cry – New Hay Fever Products And Campaigns In Germany This Spring
New OTC products and campaigns for the hay fever season from: GSK, Novartis, Dermapharm, Galenpharma, DHU and Thea Pharma.